Vitamin D Testing
Customize your policy alerts
Sign up for medical mutual - ohio Policy AHS - G2005 alerts
Get alerted when Policy AHS - G2005 changes without checking for updates manually.
Monitor payer policy activity
Coverage and clinical criteria for serum vitamin D testing (25-hydroxyvitamin D and 1,25-dihydroxyvitamin D), including D2/D3 fraction testing, for Medical Mutual - Ohio members.
Combined CC1 and CC3 into a single coverage criterion allowing 25-hydroxyvitamin D serum testing no more than once every six months for specified patient groups.
Chemotherapy was added to Note 1, letter N as a medication known to lower vitamin D levels.
Note 1, letter DD and Note 2, letter N updated to read 'Chronic Kidney Disease and End Stage Renal Disease'.
Added 'Granulomatous' to Note 1 and Note 2.
Coverage Criteria for Vitamin D Testing
Covered indications
Covered when the specified conditions below are met
Refer to Note 1 for list of qualifying conditions (see Note 1, letters A–FF).
Included as part of total 25(OH)D analysis.
Refer to Note 2 for qualifying indications (disorders of calcium metabolism, renal disease, granulomatous disorders, etc.).
Indications for targeted testing / when covered
Covered when testing is ordered for patients with risk factors or clinical conditions associated with potential vitamin D deficiency, as supported by specialty guidance.
References: AACE/ACE, ROS, AAP, and bariatric surgery society guidance.
Not routinely covered / screening discouraged
Testing is generally not supported for routine screening in asymptomatic general population groups.
Guideline sources (Endocrine Society, USPSTF, AAP, Manchester University NHS Trust) advise against population screening or find evidence insufficient.
Retesting and monitoring criteria
Retesting is appropriate only when clinically indicated and not earlier than recommended intervals.
RACGP and Manchester University NHS Trust guidance: retest no earlier than 3 months and preferably not within 6 months; retesting within 4 weeks after a large loading dose may give misleading results.
Combined CC (previously CC1 and CC3)
Covered when ALL of the following are met
See Note 1 and Note 2 for qualifying conditions; Note 1 letter N now explicitly includes chemotherapy as a medication known to lower vitamin D; Note DD and Note 2 N updated to 'Chronic Kidney Disease and End Stage Renal Disease'.
Measurement of serum vitamin D is guided by clinical indications. Serum 25-hydroxyvitamin D (25OHD) testing is the recommended analyte for assessing vitamin D status and is covered when ordered for individuals with conditions specifically associated with vitamin D deficiency or decreased bone density, for suspected hypervitaminosis D, or for known vitamin D deficiency. The policy explicitly states that measurement of serum 1,25-dihydroxyvitamin D to screen for deficiency and routine screening of asymptomatic individuals do not meet coverage criteria.
Routine population screening of asymptomatic individuals is discouraged. Multiple guideline sources cited in the policy — including the Endocrine Society and the American Academy of Pediatrics — recommend against routine 25(OH)D testing in the general adult population, during pregnancy, and in otherwise healthy children without risk factors. Testing should be targeted to patients with clinical indications or risk factors described in the policy notes rather than performed as population screening.
The policy includes frequency limitations that operationally exclude repeat testing more often than every six months for covered indications. Retesting intervals are intended to allow sufficient time for serum concentrations to change after intervention; therefore, repeat 25‑hydroxyvitamin D testing performed more frequently than once every six months would not meet the revised coverage criterion except where otherwise noted in the qualifying conditions.
The policy delineates the appropriate role of 1,25-dihydroxyvitamin D testing: it is covered for evaluation or management of conditions associated with defects in vitamin D metabolism but is not appropriate for routine screening to assess vitamin D status. For routine assessment of vitamin D status, 25-hydroxyvitamin D is the recommended and more stable analyte.
Repeat testing guidance emphasizes clinical timing: do not retest within 3 months of initiating vitamin D replacement (including after a large loading dose), because early retesting may not reflect the true response to supplementation and can give misleading results. Many guidelines advise waiting up to six months before reassessment when monitoring therapy.
Requests for 25-hydroxyvitamin D testing that occur more frequently than the policy limit of one test every six months for the covered indications are outside the updated coverage criteria and may be considered not medically necessary or subject to utilization review.
Covered Indications and Qualifying Conditions
inv-39: Individuals with diseases/conditions specifically associated with vitamin D deficiency or decreased bone density; suspected hypervitaminosis D; individuals with vitamin D deficiency; evaluation/treatment of defects in vitamin D metabolism.
See full Note 1 in policy for alphabetical list (A–FF).
Refer to Note 2 for complete list.
inv-40: Assessment of vitamin D status in patients with or at risk for bone disease (osteoporosis, low BMD), symptomatic deficiency, malabsorption, preoperative and postoperative evaluation for bariatric surgery patients.
Guidance sources: AACE/ACE, ROS, and bariatric surgery society recommendations.
inv-41: Individuals with an underlying disease or condition specifically associated with vitamin D deficiency or decreased bone density; individuals suspected of hypervitaminosis of vitamin D; individuals with vitamin D deficiency. (chemotherapy added as medication known to lower vitamin D)
See Note 1 and Note 2 for full qualifying condition lists.
Testing Frequency Limits
Procedure Codes and Thresholds
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed |
| 82652 | Vitamin D; 1, 25 dihydroxy, includes fraction(s), if performed |
| 0038U | Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative Proprietary test: Sensieva ™ Droplet 25OH Vitamin D2/D3 Microvolume LC/MS Assay |
Provider Actions, Documentation, and Billing Guidance
Procedure codes and review
Procedure codes for vitamin D testing are listed below. Use these codes on claims and expect standard coding review for medical necessity and frequency limits.
- 82306 — Vitamin D; 25 hydroxy, includes fraction(s), if performed
- 82652 — Vitamin D; 1,25 dihydroxy, includes fraction(s), if performed
- 0038U — Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative (Proprietary test: Sensieva™ Droplet 25OH Vitamin D2/D3 Microvolume LC/MS Assay)
Required coverage determination for vitamin D assay codes
Testing for 25-hydroxyvitamin D (and D2/D3 fractions) is covered only when the policy's clinical coverage criteria are met. The policy incorporates a universal frequency limit: no more than one 25-hydroxyvitamin D test every six months for covered indications.
1,25-dihydroxyvitamin D screening excluded
Measurement of serum 1,25-dihydroxyvitamin D is NOT appropriate for screening for vitamin D deficiency and does not meet coverage criteria when used for that purpose. 1,25-dihydroxyvitamin D testing is covered only for evaluation or treatment of conditions associated with defects in vitamin D metabolism as listed in Note 2.
Early repeat testing risk
Retesting too soon after an intervention or supplementation is discouraged. Evidence and guideline recommendations advise against early repeat testing because serum levels may not have had time to respond.
- Avoid repeat 25‑OH vitamin D testing within 3 months of starting supplementation; many recommendations prefer waiting 3–6 months.
- Retesting within 4 weeks of a large loading dose can give false evidence of over-repletion.
- Early repeat testing may be denied if performed before the policy frequency limit or guideline-recommended interval.
Clinical indication documentation
Document the clinical indication when ordering 25‑hydroxyvitamin D testing. Orders should align with the policy's listed indications for testing (Note 1 for 25‑OH testing and Note 2 for 1,25‑OH testing). Routine screening in asymptomatic individuals is excluded.
- State the specific indication on the order (e.g., 'malabsorption', 'post‑bariatric surgery', 'long‑term glucocorticoid therapy').
- Do not order for general screening in asymptomatic patients without a listed indication.
Required clinical documentation
When submitting requests for coverage or prior authorization (if applicable), include pertinent biochemical data and prior vitamin D measurements to support medical necessity.
- Provide recent serum calcium and phosphorus levels.
- Include alkaline phosphatase and parathyroid hormone (PTH) results when available.
- Attach previous 25‑OH vitamin D test results if monitoring response to therapy (noting date and value).
Ordering documentation
Orderers must document the indication on the lab order and adhere to the policy frequency limit of no more than one 25‑hydroxyvitamin D test every six months for covered indications.
- Include the clinical reason on the requisition when ordering (e.g., monitoring supplementation for documented deficiency, evaluation of disorders listed in Note 1).
- If monitoring therapy, indicate prior result date and value; testing more frequently than every 6 months may be outside coverage.
Therapeutic monitoring implication
Measurement of 25‑hydroxyvitamin D may be used for therapeutic monitoring in certain populations (for example, individuals on chronic glucocorticoid therapy >3 months, patients with malabsorption, or those receiving high‑dose supplementation), provided monitoring adheres to the policy frequency limit.
- Document that testing is being used to guide supplementation or therapeutic decisions (e.g., dose adjustment).
- Therapeutic monitoring should respect the policy limit of one test per six months except where clinical justification for earlier testing is documented and medically necessary.
Empiric treatment vs testing
For certain high‑risk, asymptomatic individuals, empiric vitamin D supplementation without prior laboratory measurement is acceptable and recommended by some guidelines; avoid unnecessary testing in these groups.
- Treat asymptomatic high‑risk adults (e.g., those with risk factors for deficiency) empirically with supplementation rather than routine testing when appropriate.
- Reserve testing for individuals with symptoms, complications, or when results will change management.
Providers: ensure all required elements (indication, relevant labs, prior results, and adherence to frequency limits) are included with orders to avoid claim denials or requests for additional information.
Ordering Requirements
Order tests based on policy clinical indications
Order vitamin D tests only when the clinical indications listed in the policy are present (underlying diseases, disorders of vitamin D metabolism, medications affecting vitamin D).
- See Note 1 and Note 2 for full lists of qualifying conditions and medications.
Order tests for listed clinical conditions (osteoporosis, malabsorption, bariatric patients, symptomatic deficiency)
Place orders for testing when clinically indicated by the conditions listed (for example, osteoporosis/low BMD, malabsorption, pre/post bariatric surgery, or symptomatic deficiency).
- ROS and AACE guidance cited for osteoporosis‑related testing recommendations.
Use referenced codes and document indication; follow frequency limits
When ordering, use the referenced CPT/HCPCS codes and document the clinical indication consistent with the policy; adhere to the stated frequency limits to avoid denial.
Services Not Covered
The policy does not support routine population screening for vitamin D deficiency in asymptomatic individuals; it also specifies that measurement of serum 1,25-dihydroxyvitamin D for general screening purposes does not meet coverage criteria. Orders for vitamin D testing should be limited to the clinical indications and qualifying conditions listed in the policy notes.
Routine screening of asymptomatic groups — including the general adult population, healthy children without risk factors, and routine pregnancy screening — is not routinely supported and therefore not covered. Guideline statements cited in the policy (e.g., Endocrine Society, USPSTF, AAP) advise against population‑based screening and recommend targeted measurement only for individuals with relevant clinical indications.
Repeat 25-hydroxyvitamin D testing more frequently than once every six months for covered indications is not supported by the revised coverage criteria. The policy combines prior criteria to enforce a universal six‑month frequency limit for 25‑OH vitamin D testing in the specified patient groups.
Definitions and Test Names
Background and Rationale
For clinical context, 25-hydroxyvitamin D (25OHD) is the predominant and most stable circulating form used to assess vitamin D status and is therefore the primary analyte for testing. By contrast, 1,25-dihydroxyvitamin D is the active metabolite with a much shorter circulating half-life and is reserved for evaluation of specific metabolic defects rather than routine status screening.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.